TXG
10x Genomics, Inc. [TXG] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
TXG Stock Summary
Top 10 Correlated ETFs
TXG
Top 10 Correlated Stocks
TXG
In the News
Cathie Wood Just Bought These 3 Biotech Stocks. Should You Buy, Too?
The U.S. spends approximately $450 billion every year treating rare diseases. Investing guru Cathie Wood says managing patients afflicted with these illnesses could cost $20 trillion over their lifetime.
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Ark Invest bought shares of Roku, 10x Genomics, and Intellia Therapeutics on Monday. Roku has shed more than one-third of its value over the past two weeks after a series of unfortunate events.
10x Genomics, Inc. (TXG) Q4 2023 Earnings Call Transcript
10x Genomics, Inc. (TXG) Q4 2023 Earnings Call Transcript
Here's What Key Metrics Tell Us About 10x Genomics (TXG) Q4 Earnings
Although the revenue and EPS for 10x Genomics (TXG) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
10x Genomics (TXG) Reports Q4 Loss, Tops Revenue Estimates
10x Genomics (TXG) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.15 per share a year ago.
10x Genomics (TXG) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
10x Genomics: Still Waiting For Entry
10x Genomics reported 18% YoY revenue growth in Q4, reaching $184M, with instruments revenue seeing a remarkable surge of 71%. The company celebrated the successful launch of its cutting-edge platform, Xenium, which offers exceptional vision and surpasses competitors in speed, sensitivity, and specificity. 10x Genomics is poised for sustained growth with its pursuit of scientific advancements, expanding applications in various fields, and strategic partnerships.
10x Genomics: Unveiling The Investment Potential
10x Genomics is a life science technology company with a clear mission and visionary leadership. 10x Genomics delivered a solid Q3 quarter with revenue reaching $154M, growing 17% YoY. The company has a huge growth opportunity in the genomics market thanks to its razor-blade business model and innovative product roadmap.
10x Genomics, Inc. (TXG) Q3 2023 Earnings Call Transcript
10x Genomics, Inc. (NASDAQ:TXG ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Cassie Corneau - Director, Investor Relations and Strategic Finance Serge Saxonov - CEO and Co-Founder Justin McAnear - Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Dan Arias - Stifel Kyle Mikson - Canaccord Genuity Dan Brennan - TD Cowen Salem Salem - Barclays Tejas Savant - Morgan Stanley John Sourbeer - UBS Mason Carrico - Stephens Michael Ryskin - Bank of America Justin Bowers - Deutsche Bank Rachel Vatnsdal - JPMorgan Operator Thank you for standing by. My name is Aaron, and I will be your conference operator for today.
10x Genomics (TXG) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for 10x Genomics (TXG) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
TXG Financial details
TXG Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 2.55 | 2.95 | 4.44 | 4.54 | 5.28 | |
| Net income per share | -0.32 | -5.37 | -0.53 | -1.46 | -2.18 | |
| Operating cash flow per share | 0.36 | -2.15 | -0.19 | -0.3 | -0.13 | |
| Free cash flow per share | -0.08 | -2.53 | -1.11 | -1.45 | -0.55 | |
| Cash per share | 4.41 | 6.56 | 5.32 | 3.78 | 3.32 | |
| Book value per share | 4.36 | 7.31 | 7.41 | 7.08 | 6.32 | |
| Tangible book value per share | 4.13 | 7.09 | 7.14 | 6.84 | 6.14 | |
| Share holders equity per share | 4.36 | 7.31 | 7.41 | 7.08 | 6.32 | |
| Interest debt per share | 0.34 | 0.64 | 0.75 | 0.84 | 0.81 | |
| Market cap | 7.34B | 14.32B | 16.44B | 4.15B | 6.56B | |
| Enterprise value | 6.94B | 13.72B | 15.93B | 4.02B | 6.29B | |
| P/E ratio | -234.82 | -26.39 | -282.32 | -24.99 | -25.7 | |
| Price to sales ratio | 29.84 | 47.93 | 33.51 | 8.03 | 10.6 | |
| POCF ratio | 211.93 | -65.73 | -769.07 | -123.46 | -431.44 | |
| PFCF ratio | -901.53 | -55.89 | -134.02 | -25.1 | -101.3 | |
| P/B Ratio | 17.47 | 19.38 | 20.11 | 5.15 | 8.85 | |
| PTB ratio | 17.47 | 19.38 | 20.11 | 5.15 | 8.85 | |
| EV to sales | 28.24 | 45.92 | 32.48 | 7.79 | 10.17 | |
| Enterprise value over EBITDA | -262.51 | -166.42 | -297.74 | -24.92 | -39.76 | |
| EV to operating cash flow | 200.54 | -62.98 | -745.42 | -119.75 | -414.07 | |
| EV to free cash flow | -853.07 | -53.54 | -129.9 | -24.35 | -97.23 | |
| Earnings yield | 0 | -0.04 | 0 | -0.04 | -0.04 | |
| Free cash flow yield | 0 | -0.02 | -0.01 | -0.04 | -0.01 | |
| Debt to equity | 0.07 | 0.09 | 0.1 | 0.12 | 0.13 | |
| Debt to assets | 0.05 | 0.07 | 0.08 | 0.09 | 0.1 | |
| Net debt to EBITDA | 14.91 | 7.28 | 9.45 | 0.77 | 1.67 | |
| Current ratio | 7.63 | 6.56 | 6.77 | 4.85 | 4.69 | |
| Interest coverage | -9.44 | -50.73 | -61.1 | -352.82 | -6.12K | |
| Income quality | -1.11 | 0.4 | 0.37 | 0.2 | 0.06 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.53 | 0.67 | 0.52 | 0.57 | 0 | |
| Research and developement to revenue | 0.34 | 0.41 | 0.43 | 0.51 | 0.44 | |
| Intangibles to total assets | 0.04 | 0.02 | 0.03 | 0.03 | 0.02 | |
| Capex to operating cash flow | -1.24 | 0.18 | 4.74 | 3.92 | 3.26 | |
| Capex to revenue | -0.17 | -0.13 | -0.21 | -0.25 | -0.08 | |
| Capex to depreciation | -6.05 | -2.02 | -3.58 | -3.99 | -1.14 | |
| Stock based compensation to revenue | 0.05 | 0.16 | 0.2 | 0.26 | 0.27 | |
| Graham number | 5.65 | 29.7 | 9.38 | 15.24 | 17.6 | |
| ROIC | -0.07 | -0.1 | -0.06 | -0.17 | -0.22 | |
| Return on tangible assets | -0.05 | -0.6 | -0.06 | -0.17 | -0.27 | |
| Graham Net | 2.82 | 5.21 | 4.35 | 2.86 | 2.45 | |
| Working capital | 417.79M | 656.24M | 637.23M | 504.08M | 468.86M | |
| Tangible asset value | 397.72M | 716.72M | 787.66M | 778.37M | 719.92M | |
| Net current asset value | 295M | 584.1M | 546.33M | 411.8M | 371.92M | |
| Invested capital | 0.07 | 0.09 | 0.1 | 0.12 | 0.13 | |
| Average receivables | 31.47M | 42.29M | 68.23M | 94.73M | 109.52M | |
| Average payables | 10.91M | 8.87M | 11.03M | 19.48M | 18.67M | |
| Average inventory | 11.92M | 22.61M | 44.96M | 70.8M | 77.67M | |
| Days sales outstanding | 49.54 | 62.54 | 63.44 | 73.66 | 67.74 | |
| Days payables outstanding | 77.91 | 29.4 | 85.48 | 65.49 | 27.43 | |
| Days of inventory on hand | 91.32 | 187.03 | 295.41 | 247.49 | 128.47 | |
| Receivables turnover | 7.37 | 5.84 | 5.75 | 4.96 | 5.39 | |
| Payables turnover | 4.68 | 12.42 | 4.27 | 5.57 | 13.31 | |
| Inventory turnover | 4 | 1.95 | 1.24 | 1.47 | 2.84 | |
| ROE | -0.07 | -0.73 | -0.07 | -0.21 | -0.34 | |
| Capex per share | -0.44 | -0.38 | -0.92 | -1.16 | -0.42 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.36 | 1.16 | 1.26 | 1.31 | 1.55 | |
| Net income per share | -0.15 | -0.44 | -0.53 | -0.79 | -0.41 | |
| Operating cash flow per share | 0.12 | -0.04 | -0.1 | -0.21 | 0.22 | |
| Free cash flow per share | -0.23 | -0.08 | -0.32 | -0.35 | 0.19 | |
| Cash per share | 3.75 | 3.62 | 3.35 | 3.03 | 3.28 | |
| Book value per share | 7.02 | 6.94 | 6.8 | 6.33 | 6.25 | |
| Tangible book value per share | 6.78 | 6.7 | 6.57 | 6.11 | 6.07 | |
| Share holders equity per share | 7.02 | 6.94 | 6.8 | 6.33 | 6.25 | |
| Interest debt per share | 0.83 | 0.88 | 0.85 | 0.84 | 0.8 | |
| Market cap | 4.18B | 6.45B | 6.52B | 4.86B | 6.63B | |
| Enterprise value | 4.06B | 6.22B | 6.29B | 4.64B | 6.37B | |
| P/E ratio | -60.73 | -31.78 | -26.1 | -13.06 | -33.88 | |
| Price to sales ratio | 26.77 | 48.04 | 44.39 | 31.61 | 36.06 | |
| POCF ratio | 304.73 | -1.56K | -565.41 | -191.92 | 257.59 | |
| PFCF ratio | -160.77 | -685.71 | -176.7 | -119.2 | 297.42 | |
| P/B Ratio | 5.19 | 8.04 | 8.21 | 6.52 | 8.95 | |
| PTB ratio | 5.19 | 8.04 | 8.21 | 6.52 | 8.95 | |
| EV to sales | 25.97 | 46.32 | 42.85 | 30.22 | 34.63 | |
| Enterprise value over EBITDA | -249.12 | -125.32 | -103.53 | -50.61 | -266.53 | |
| EV to operating cash flow | 295.65 | -1.51K | -545.78 | -183.51 | 247.34 | |
| EV to free cash flow | -155.98 | -661.23 | -170.56 | -113.98 | 285.59 | |
| Earnings yield | 0 | -0.01 | -0.01 | -0.02 | -0.01 | |
| Free cash flow yield | -0.01 | 0 | -0.01 | -0.01 | 0 | |
| Debt to equity | 0.12 | 0.13 | 0.13 | 0.13 | 0.13 | |
| Debt to assets | 0.09 | 0.1 | 0.1 | 0.1 | 0.1 | |
| Net debt to EBITDA | 7.65 | 4.64 | 3.72 | 2.32 | 11.04 | |
| Current ratio | 4.85 | 5.37 | 5.94 | 5.37 | 4.69 | |
| Interest coverage | -184.77 | -2.74K | -12.67K | -94.8K | -4.45K | |
| Income quality | -0.8 | 0.08 | 0.18 | 0.27 | -0.53 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.48 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.41 | 0.5 | 0.49 | 0.7 | 0.3 | |
| Intangibles to total assets | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | |
| Capex to operating cash flow | -2.9 | 1.28 | 2.2 | 0.61 | -0.13 | |
| Capex to revenue | -0.25 | -0.04 | -0.17 | -0.1 | -0.02 | |
| Capex to depreciation | -4.69 | -0.61 | -2.13 | -1.35 | -0.29 | |
| Stock based compensation to revenue | 0.26 | 0.31 | 0.31 | 0.26 | 0.21 | |
| Graham number | 4.87 | 8.28 | 9.04 | 10.61 | 7.62 | |
| ROIC | -0.02 | -0.05 | -0.07 | -0.1 | -0.04 | |
| Return on tangible assets | -0.02 | -0.05 | -0.06 | -0.1 | -0.05 | |
| Graham Net | 2.84 | 2.65 | 2.59 | 2.31 | 2.43 | |
| Working capital | 504.08M | 489.89M | 484.85M | 457.63M | 468.86M | |
| Tangible asset value | 778.37M | 774.93M | 766.5M | 718.87M | 719.92M | |
| Net current asset value | 411.8M | 390.25M | 386.6M | 359.02M | 371.92M | |
| Invested capital | 0.12 | 0.13 | 0.13 | 0.13 | 0.13 | |
| Average receivables | 93.88M | 91.08M | 82.81M | 95.77M | 109.34M | |
| Average payables | 21.6M | 25.46M | 26.22M | 20.98M | 17.29M | |
| Average inventory | 80.13M | 81.97M | 83M | 82.3M | 77.31M | |
| Days sales outstanding | 60.03 | 52.24 | 53.75 | 60.83 | 56.17 | |
| Days payables outstanding | 52.78 | 73.51 | 44.09 | 29.17 | 18.18 | |
| Days of inventory on hand | 199.49 | 206.37 | 159.55 | 125.31 | 85.14 | |
| Receivables turnover | 1.5 | 1.72 | 1.67 | 1.48 | 1.6 | |
| Payables turnover | 1.71 | 1.22 | 2.04 | 3.09 | 4.95 | |
| Inventory turnover | 0.45 | 0.44 | 0.56 | 0.72 | 1.06 | |
| ROE | -0.02 | -0.06 | -0.08 | -0.12 | -0.07 | |
| Capex per share | -0.35 | -0.05 | -0.22 | -0.13 | -0.03 |
TXG Frequently Asked Questions
What is 10x Genomics, Inc. stock symbol ?
10x Genomics, Inc. is a US stock , located in Pleasanton of Ca and trading under the symbol TXG
What is 10x Genomics, Inc. stock quote today ?
10x Genomics, Inc. stock price is $30.785 today.
Is 10x Genomics, Inc. stock public?
Yes, 10x Genomics, Inc. is a publicly traded company.
Company Profile
- Volume Average 1.36M
- Market Capitalization 4.12B
- Employee 1.26K
- CEO Dr. Serge Saxonov Ph.D.
- Headquarters Pleasanton,CA,US
- IPO Date 2019-09-12
-
Website
https://www.10xgenomics.com 
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
